Jenburkt Pharmaceuticals Ltd. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 134395,
    "name": "Jenburkt Pharma",
    "stock_name": "Jenburkt Pharma",
    "full_name": "Jenburkt Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/jenburkt-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,150.90",
    "chg": 76.4,
    "chgp": "7.11%",
    "dir": 1,
    "prev_price": "1,074.50",
    "mcapval": "510.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524731,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE354A01013",
    "curr_date": "May 06",
    "curr_time": "",
    "bse_nse_vol": "13.51 k",
    "exc_status": "Active",
    "traded_date": "May 06, 2026",
    "traded_date_str": "2026 05 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-jenburkt-pharmaceuticals-ltd-latest-results-good-or-bad-3978370",
        "imagepath": "",
        "date": "2026-05-06 19:15:07",
        "description": "Jenburkt Pharmaceuticals Ltd. has reported its financial results for Q4 FY26, showcasing notable operational trends. The company achieved net sales of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% from ₹43.02 crores in Q3 FY26, and an 8.72% increase compared to ₹41.05 crores in Q4 FY25. This modest revenue growth is complemented by a significant improvement in profitability, with net profit reaching ₹10.85 crores, which is an 82.97% increase from the previous quarter's ₹5.93 crores.\n\nA key highlight of the quarter was the operating margin, which surged to 31.93%, up from 17.25% in Q3 FY26. This substantial margin recovery, representing a 1,468 basis point expansion, was primarily driven by a significant reduction in employee costs, which decreased from ₹14.71 crores to ₹9.52 crores. The improvement in operational efficiency is further evidenced by the operating profit before depreciation, i..."
      },
      {
        "title": "Jenburkt Pharmaceuticals Q4 FY26: Margin Expansion Drives Strong Quarter Despite Modest Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/jenburkt-pharmaceuticals-q4-fy26-margin-expansion-drives-strong-quarter-despite-modest-revenue-growth-3977897",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_quaterlyResult_3977897.png",
        "date": "2026-05-06 10:01:35",
        "description": "Jenburkt Pharmaceuticals Ltd., a speciality pharmaceutical formulations manufacturer operating across 13 countries, delivered a mixed performance in Q4 FY26 (Mar'26), with net profit surging 27.05% quarter-on-quarter to ₹10.85 crores despite modest revenue growth of 3.74%. The ₹510 crore market capitalisation company demonstrated impressive margin expansion, with operating profit margin (excluding other income) reaching a seven-quarter high of 31.93%, up from 17.25% in the previous quarter. The stock responded positively to the results, gaining 7.03% on May 06, 2026, to close at ₹1,150.00, reflecting investor confidence in the company's operational efficiency improvements."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3973162",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/JenburktPharmac_mojoScore_3973162.png",
        "date": "2026-05-04 10:10:30",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "When is the next results date for Jenburkt Pharmaceuticals Ltd.?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-jenburkt-pharmaceuticals-ltd-3969170",
        "imagepath": "",
        "date": "2026-04-29 23:16:07",
        "description": "The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for 05 May 2026...."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3958962",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/JenburktPharmac_mojoScore_3958962.png",
        "date": "2026-04-23 10:10:41",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3943400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/JenburktPharmac_mojoScore_3943400.png",
        "date": "2026-04-12 10:10:23",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3928440",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/JenburktPharmac_mojoScore_3928440.png",
        "date": "2026-04-01 10:10:03",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3905001",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JenburktPharmac_mojoScore_3905001.png",
        "date": "2026-03-21 10:10:03",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-3882643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JenburktPharmac_mojoScore_3882643.png",
        "date": "2026-03-10 10:10:02",
        "description": "Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      }
    ],
    "total": 502,
    "sid": "134395",
    "stock_news_url": "https://www.marketsmojo.com/news/jenburkt-pharmaceuticals-134395"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Taking On Record The Audited Financial Results For The Quarter And Financial Year Ended On 31St March 2026 And To Consider Recommendation Of Dividend If Any.",
      "datetime": "28-Apr-2026",
      "details": "Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve the audited results for the quarter and financial year ended on 31st March 2026 and to consider recommendation of dividend if any.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures Pursuant To SEBI Circular Dated 10Th August 2021 :Not A Large Corporate",
      "datetime": "14-Apr-2026",
      "details": "Pursuant to SEBI Circular dated 10th August 2021 we hereby confirm that for the financial year ended 31st March 2026 Jenburkt pharmaceuticals Limited is not a large corporate as per applicability criteria mentioned in clause 2.11 of chapter XII therein.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Apr-2026",
      "details": "Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jenburkt Pharmaceuticals Ltd. has declared <strong>180%</strong> dividend, ex-date: 11 Jul 25",
          "dt": "2025-07-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

2026-05-06 19:15:07

Jenburkt Pharmaceuticals Ltd. has reported its financial results for Q4 FY26, showcasing notable operational trends. The company achieved net sales of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% from ₹43.02 crores in Q3 FY26, and an 8.72% increase compared to ₹41.05 crores in Q4 FY25. This modest revenue growth is complemented by a significant improvement in profitability, with net profit reaching ₹10.85 crores, which is an 82.97% increase from the previous quarter's ₹5.93 crores. A key highlight of the quarter was the operating margin, which surged to 31.93%, up from 17.25% in Q3 FY26. This substantial margin recovery, representing a 1,468 basis point expansion, was primarily driven by a significant reduction in employee costs, which decreased from ₹14.71 crores to ₹9.52 crores. The improvement in operational efficiency is further evidenced by the operating profit before depreciation, i...

Read full news article

Jenburkt Pharmaceuticals Q4 FY26: Margin Expansion Drives Strong Quarter Despite Modest Revenue Growth

2026-05-06 10:01:35

Jenburkt Pharmaceuticals Ltd., a speciality pharmaceutical formulations manufacturer operating across 13 countries, delivered a mixed performance in Q4 FY26 (Mar'26), with net profit surging 27.05% quarter-on-quarter to ₹10.85 crores despite modest revenue growth of 3.74%. The ₹510 crore market capitalisation company demonstrated impressive margin expansion, with operating profit margin (excluding other income) reaching a seven-quarter high of 31.93%, up from 17.25% in the previous quarter. The stock responded positively to the results, gaining 7.03% on May 06, 2026, to close at ₹1,150.00, reflecting investor confidence in the company's operational efficiency improvements.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-05-04 10:10:30

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

When is the next results date for Jenburkt Pharmaceuticals Ltd.?

2026-04-29 23:16:07

The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for 05 May 2026....

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-04-23 10:10:41

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-04-12 10:10:23

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-04-01 10:10:03

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-03-21 10:10:03

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Jenburkt Pharmaceuticals Ltd. is Rated Sell

2026-03-10 10:10:02

Jenburkt Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 10 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

View All News